Compare LAD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAD | TGTX |
|---|---|---|
| Founded | 1946 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.5B |
| IPO Year | 1996 | 2008 |
| Metric | LAD | TGTX |
|---|---|---|
| Price | $304.28 | $53.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $447.73 | $69.71 |
| AVG Volume (30 Days) | 238.0K | ★ 1.4M |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | 9.01 | ★ 1746.67 |
| EPS | ★ 15.68 | 0.17 |
| Revenue | ★ $11,821,400,000.00 | $2,785,000.00 |
| Revenue This Year | $2.15 | $55.80 |
| Revenue Next Year | $3.61 | $37.28 |
| P/E Ratio | ★ $18.45 | $328.53 |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $239.78 | $26.76 |
| 52 Week High | $439.49 | $59.30 |
| Indicator | LAD | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.02 | 52.86 |
| Support Level | $283.88 | $51.76 |
| Resistance Level | $302.28 | $58.26 |
| Average True Range (ATR) | 12.62 | 2.13 |
| MACD | -4.38 | -0.16 |
| Stochastic Oscillator | 8.74 | 56.39 |
Lithia Motors is a retailer of new and used vehicles and related services. The company offers nearly 60 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US. We expect more deals over time in the US and, at times, abroad. Annual revenue in 2025 was $37.6 billion, and we see over $50 billion possible in a few years. The US was 78.5% of 2025 revenue and the UK second at 18.4%, due to the 2024 Pendragon acquisition. In 2025, new vehicle sales were about 50% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.